2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
Status:
Terminated
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label extension study in patients with mild Alzheimer's disease who have
completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive
azeliragon 5 mg/day for up to 2 years.